Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity
NCT ID: NCT02769013
Last Updated: 2020-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
380 participants
OBSERVATIONAL
2016-04-30
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. In Work Package 1 (WP1) the investigators will assess whether S. haematobium infection increases the human reservoir of P. falciparum by increasing the carriage rate and incidence of P. falciparum gametocytaemia as well as by increasing the proportion and incidence of subject with sub-microscopic P. falciparum infection. The investigators will also determine whether this increase in gametocyte carriage is a consequence of an impairment of the immune response of helminth infected subjects to P. falciparum.
2. In Work Package 2 (WP2) the investigators will determine whether the transmission of the sexual forms of P. falciparum from the human host to mosquito is increased in S. haematobium infected subjects compared to uninfected controls. Moreover the investigators will study whether the immunological changes induced in S. haematobium infected subjects lead to a decrease of the transmission reducing activity of IgG specific to Pfs48/45 and Pfs230 (both capable of blocking/impairing further development of P. falciparum in the mosquito gut).
3. Finally in Work Package 3 (WP3) the investigators will assess whether S. haematobium infection affects the transmission of P. falciparum from the mosquito to the human host. This effect will be determined indirectly by assessing whether S. haematobium infected subjects are more attractive to mosquitoes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
S. haematobium positives in Gabon
Asymptomatic volunteers infected with S. haematobium and living in Gabon
Pre-treatment follow up
No active intervention; medical support provided if needed
S. haematobium treatment
Praziquantel-treatment for S. haematobium positive volunteers
Post treatment follow up
No active intervention; medical support provided if needed.
Olfactometer experiment
No active intervention; medical support provided if needed.
S. haematobium negatives in Gabon
Volunteers not infected with S. haematobium and living in Gabon
Pre-treatment follow up
No active intervention; medical support provided if needed
Post treatment follow up
No active intervention; medical support provided if needed.
Olfactometer experiment
No active intervention; medical support provided if needed.
S. haematobium positives in Ghana
Asymptomatic volunteers infected with S. haematobium and living in Ghana
Pre-treatment follow up
No active intervention; medical support provided if needed
S. haematobium treatment
Praziquantel-treatment for S. haematobium positive volunteers
Post treatment follow up
No active intervention; medical support provided if needed.
Olfactometer experiment
No active intervention; medical support provided if needed.
S. haematobium negatives in Ghana
Volunteers not infected with S. haematobium and living in Ghana
Pre-treatment follow up
No active intervention; medical support provided if needed
Post treatment follow up
No active intervention; medical support provided if needed.
Olfactometer experiment
No active intervention; medical support provided if needed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pre-treatment follow up
No active intervention; medical support provided if needed
S. haematobium treatment
Praziquantel-treatment for S. haematobium positive volunteers
Post treatment follow up
No active intervention; medical support provided if needed.
Olfactometer experiment
No active intervention; medical support provided if needed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Without severe or moderate disease
* Agreement to be enrolled in the study (written informed consent or consent by the legal representative and assent)
* Living in the study area for at least 1 year
Exclusion Criteria
* Know sickle cell disease
* Macroscopic haematuria
* Any other know severe disease
6 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulysse ATEBA NGOA, Dr.
Role: PRINCIPAL_INVESTIGATOR
CERMEL, Lambarene, GABON
Oumou MAIGA, PhD
Role: PRINCIPAL_INVESTIGATOR
KCCR, Kumasi, Ghana
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ayôla Akim ADEGNIKA
Lambaréné, Albert Schweitzer Hospital, Gabon
KCCR
Kumasi, , Ghana
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Edoa JR, Adegbite BR, Honkpehedji YJ, Zinsou JF, Boussougou-Sambe ST, Woldearegai TG, Mordmuller B, Adegnika AA, Dejon-Agobe JC. Epidemiology of soil-transmitted helminth infections and the differential effect of treatment on the distribution of helminth species in rural areas of Gabon. Trop Med Health. 2024 Jan 2;52(1):3. doi: 10.1186/s41182-023-00567-z.
Dejon-Agobe JC, Edoa JR, Honkpehedji YJ, Zinsou JF, Adegbite BR, Ngwese MM, Mangaboula A, Lell B, Woldearegai TG, Grobusch MP, Mordmuller B, Adegnika AA. Schistosoma haematobium infection morbidity, praziquantel effectiveness and reinfection rate among children and young adults in Gabon. Parasit Vectors. 2019 Dec 10;12(1):577. doi: 10.1186/s13071-019-3836-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Transmal study version 2.0
Identifier Type: -
Identifier Source: org_study_id